WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Zeena A. Shnawa and Adil R. Al Saadawi

ABSTRACT

Background: Worldwide, 2,3 million women were diagnosed with breast cancer in 2020, killing 685 000. Breast cancer was the world's most common cancer in 2020, with 7.8 million women diagnosed in the last five years. Breast cancer may develop after puberty in any nation, although the risk rises with age. The aim of study is to investigate the expression of estrogen, progesterone, and Her2/neu receptors as biomarkers and explore their association with various clinicopathological parameters in breast carcinoma cases. Method: Cross-sectional research of 79 breast cancer patients at Baghdad Medical City-Educational Laboratories from January 2022 to January 2023. All female data includes age (years), tumor grades, lymph node number, histological diagnosis, tumor size (cm), ER, PR, and her2/neu. Results: Of 79 breast cancer patients, the majority (84.8%) tested positive for ER and PR, while 63.3% were negative for her2/neu. Most patients were diagnosed with invasive ductal carcinoma (87.34%) and had smaller tumors when ER and PR were positive. A significant association was found between tumor grade, lymph node count, and ER/PR status, but not with her2/neu or age. Conclusion: We found that ER and PR hormone receptor statuses affect breast cancer. ER and PR positivity was connected to smaller tumors and particular grades. No age or carcinoma type connection was detected. More than histology, intrinsic tumor biology determines hormone receptor expressions, emphasizing their relevance in personalized therapy and prognosis.

[Full Text Article] [Download Certificate]